page 1 page 2 page 3 page 4 page 5 page 6 page 7 page 8 page 9 page 10 page 11 page 12 page 13 page 14 page 15 page 16 page 17 page 18 page 19 page 20 page 21 page 22 page 23 page 24 page 25 page 26 page 27 page 28 page 29 page 30 page 31 page 32 page 33 page 34 page 35 page 36 page 37 page 38 page 39 page 40 page 41 page 42 page 43 page 44 page 45 page 46 page 47 page 48 page 49 page 50 page 51 page 52 page 53 page 54 page 55 page 56 page 57 page 58 page 59 page 60 page 61 page 62 page 63 page 64 page 65 page 66 page 67 page 68 page 69 page 70 page 71 page 72 page 73 page 74 page 75 page 76 page 77 page 78 page 79 page 80 page 81 page 82 page 83 page 84 page 85 page 86 page 87 page 88 page 89 page 90 page 91 page 92 page 93 page 94 page 95 page 96 page 97 page 98 page 99 page 100 page 101 page 102 page 103 page 104 page 105 page 106 page 107 page 108 page 109 page 110 page 111 page 112 page 113 page 114 page 115 page 116 page 117 page 118 page 119 page 120 page 121 page 122 page 123 page 124 page 125 page 126 page 127 page 128 page 129 page 130 page 131 page 132 page 133 page 134 page 135 page 136 page 137 page 138 page 139 page 140 page 141 page 142 page 143 page 144 page 145 page 146 page 147 page 148 page 149 page 150 page 151 page 152 page 153 page 154 page 155 page 156 page 157 page 158 page 159 page 160 page 161 page 162 page 163 page 164 page 165 page 166 page 167 page 168 page 169 page 170 page 171 page 172 page 173 page 174 page 175 page 176 page 177 page 178 page 179 page 180 page 181 page 182 page 183 page 184 page 185 page 186
|
94INNOVATION UKINNOVATION Almirall In January 2008, Spanish drug manufacturer Almi-rall opened up an office near London, expanding its European presence. " It had been our goal to move into the UK mar-ket since we decided to expand internationally," says Carlos Gallardo, General Manager of Almirall in the UK and Ireland. " Happily, we are doing even better than anticipated." Almirall received invaluable assistance from UK Trade & Investment ( UKTI) when planning its move. " UKTI was instrumental in quickly getting us up to speed on the UK market," recalls Gallardo. " Its advisers gave us information on the local markets for dermatological and respiratory products and also put us in touch with government contacts who helped answer questions on local regulations. From beginning to end, setting up in the UK was a smooth process." For more information, visit: www. almirall. com The UK's research environment is also world class, with the country ranked as the best performer in the G8 lead-ing economies per unit of R& D spend. UK researchers are responsible for 9% of the world's scientific papers, producing 16 research papers per US$ 1m of research funding, compared to 9.2 in the USA and 3.6 in Japan. It is therefore no surprise that UK scientists have won over 70 Nobel Prizes. As a result, the UK is recognised across the world as a hotbed of activity throughout the life- sciences market - something which has attracted high levels of foreign direct investment. Recent examples include US pharma-ceuticals giant Pfizer's announcement that it is grow-ing its presence in Cambridge, focused on Regenerative Medicine Research, and United Therapeutics' decision to expand its European headquarters in Surrey, a move likely to generate significant job creation over the next few years. Given the UK's world- beating infrastructure, investor-friendly regulatory and IP environment and its potential as a springboard to mainland Europe and beyond, such high- quality investment looks set to continue long into the future. Xiangxue Pharmaceuticals In 2007, Chinese pharmaceutical company Xiangxue set up a research centre in Cambridge to investigate traditional Eastern medicines. " We looked to the UK because of its reputation as a leader in pharmaceutical research," states Frank Wu, CEO of XiangCam, Xiangxue's UK branch. " We wanted to take advantage of its world- class research institutions, and Cambridge, with its top- rate facili-ties, seemed the natural location." Before establishing its operations in the UK, Xiangxue worked closely with UK Trade & Investment ( UKTI), which provided the company with information about the local bio- medical research community, invited it to networking events and pointed the firm in the direc-tion of technology and legal specialists. " Without the help we got from organisations like UKTI, we would not have been as successful," says Wu. " We can turn to them for assistance at any time." Life- Sciences UKTI UKINNOVATION UK95 The ofice for Life sciences The establishment of the Office for Life Sciences ( OLS) in January 2009, led by Lord Drayson, Minister for Science and Innovation, clearly signals the importance that the UK places on the life- sciences industry. The Office for Life Sciences has worked in partnership with industry to agree a set of actions, published 14 July 2009 in the Life Sci-ence Blueprint. The Blueprint actions form a package of measures that has the potential to transform the UK life-sciences industry, by ensuring that the industry realises its potential as a major driver of economic growth, and of improved health and well being. Key Blueprint actions include: » Creating an Innovation Pass that will give patients faster access to cutting- edge medicines » A UK Innovation Investment Fund to invest in technology- based businesses with high- growth potential. The UK government will invest £ 150m alongside private- sector investment on an equal basis » Measures to ensure that the NHS leads the way in the uptake of groundbreaking and cost- effective medicines and technologies » £ 18 million in investment by the Technology Strategy Board to capitalise fully on the UK's leading global position in regenerative medicine. For more details of the Blueprint visit: www. bis. gov. uk/ innovation/ business_ support/ ols To contact the OLS team e- mail: ols@ bis. gsi. gov. uk Life- Sciences UKTI |